Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) Operating Expenses (2017 - 2026)

Cogent Biosciences' Operating Expenses history spans 10 years, with the latest figure at $103.6 million for Q1 2026.

  • Quarterly Operating Expenses rose 38.27% to $103.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $362.0 million through Mar 2026, up 25.5% year-over-year, with the annual reading at $333.4 million for FY2025, 20.81% up from the prior year.
  • Operating Expenses came in at $103.6 million for Q1 2026, up from $99.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $103.6 million in Q1 2026 to a low of $31.4 million in Q1 2022.
  • The 5-year median for Operating Expenses is $62.4 million (2024), against an average of $62.9 million.
  • Year-over-year, Operating Expenses skyrocketed 145.45% in 2022 and then grew 10.53% in 2025.
  • Cogent Biosciences' Operating Expenses stood at $43.7 million in 2022, then soared by 33.11% to $58.2 million in 2023, then rose by 26.63% to $73.7 million in 2024, then surged by 34.94% to $99.5 million in 2025, then rose by 4.13% to $103.6 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Operating Expenses are $103.6 million (Q1 2026), $99.5 million (Q4 2025), and $83.4 million (Q3 2025).